510(k) Report

FDA applicant

CG Bio Co., Ltd.

Seoul, KR6 decisions2013–20260 recalls

FDA records 6 decisions for CG Bio Co., Ltd. (Seoul, KR) from 2013 to 2026: 6 510(k) clearances. Most are in product codes NKB (Thoracolumbosacral Pedicle Screw System) and OMP (Negative Pressure Wound Therapy Powered…). Since 2016 its 510(k)s took a median of 265 days from receipt to decision, against 141 for FDA’s reviews in the same codes and years. Its devices cite 13 predicates, 3 of them its own earlier devices. No recall is linked to its devices.

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) refreshed weekly, last Nov 3, 2026

FIG. A — Illustration, orthopedic panel, where it files most

How often FDA has decided CG Bio Co., Ltd.’s devices, and how often a recall has named them.

FDA decisions per year

1in 2025

2013: 12016: 12023: 12025: 12026 (partial year): 2
2013high 2 (2026) · low 0 (2014)2026

2026 so far, outlined.

Recalls per year

No recall linked to its devices since 2013.

FIG. 1 — CG Bio Co., Ltd. by year, 2013–2026Sources: FDA decision databases, recall and enforcement reports · Data through Oct 25, 2026

Planning a device like CG Bio Co., Ltd.’s? A 510(k) Report ranks candidate predicates for your device by lineage, citations and recall history, with the review-time outlook.

See the 510(k) Report